Log in to search using one of your social media accounts:


New ALS drug Radicava comes with new questions as well

It is the first new drug for amyotrophic lateral sclerosis in 22 years.
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news

Related Links:

Sebastian Peters, Eva Zitzelsperger, Sabrina Kuespert, Sabine Iberl, Rosmarie Heydn, Siw Johannesen, Susanne Petri, Ludwig Aigner, Dietmar R. Thal, Andreas Hermann, Jochen H. Weishaupt, Tim-Henrik Bruun, Ulrich Bogdahn
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This article is protected by copyright. All rights reserved.
Source: Journal of Oral Rehabilitation - Category: Dentistry Authors: Tags: Original Article Source Type: research
Authors: Liu J, Wang LN Abstract Neurodegenerative movement disorders mainly include Parkinson's disease, atypical parkinsonisms, Huntington disease, and hereditary ataxia. Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis. The neuroprotective effects of riluzole have been observed in experimental models of neurodegenerative movement disorders. In this paper, we aimed to systematically analyze the efficacy and safety of riluzole for patients with neurodegenerative movement disorder. We searched the electronic databases such as PubMed, EMBASE, CINAHL, Cochran...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - Category: Internal Medicine Authors: Tags: Basic Science Research Article Source Type: research
This article is protected by copyright. All rights reserved. “Intricate and self‐perpetuating cellular interplay underlies amyotrophic lateral sclerosis (ALS). Disease stage is a key determinant of cell type‐specific molecular mechanisms”.
Source: Stem Cells - Category: Stem Cells Authors: Tags: Embryonic Stem Cells/Induced Pluripotent Stem Cells Source Type: research
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
The cover image, by Sali M. K. Farhan et al., is based on the Research Article OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia, DOI: 10.1002/ajmg.b.32606.
Source: American Journal of Medical Genetics Part B: Neuropsychiatric Genetics - Category: Genetics & Stem Cells Authors: Tags: COVER IMAGE Source Type: research
Source: Journal of Magnetic Resonance Imaging - Category: Radiology Authors: Tags: Cover Image Source Type: research
Antioxidants&Redox Signaling , Vol. 0, No. 0.
Source: Antioxidants and Redox Signaling - Category: Research Authors: Source Type: research
Condition:   Amyotrophic Lateral Sclerosis Intervention:   Dietary Supplement: Blood sample and environmental survey Sponsor:   Centre Hospitalier Universitaire de Pointe-a-Pitre Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ALS | Health